p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer

Human Pathology

Volumn 25, Issue 12, 1994, Pages 1346-1351

  Moch, H ^a,b   Sauter, G ^a,b   Mihatsch, M J ^a,b   Gudat, F ^a,b   Epper, R ^a,b   Waldman, F M ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bladder neoplasms; erbB 2; Ki67; p53

Indexed keywords

PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER GRADING; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION; GROWTH REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; GENE EXPRESSION; HUMAN; KI-67 ANTIGEN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN P53; RECEPTOR, ERBB-2; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028143341     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/0046-8177(94)90096-5     Document Type: Article

References (58)

1. DNA binding properties of murine p53
2. Suppression of human colorectal carcinoma cell growth by wild-type p53
3. Wild-type p53 can inhibit oncogene-mediated focus formation
4. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
5. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life
6. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation
7. Tumor suppressor p53: Analysis of wild-type and mutant p53 complexes
8. Overexpression and mutation of p53 in epithelial ovarian cancer
9. Increased expression of mutant forms of p53 oncogene in primary lung cancer
10. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
11. The p53 tumor suppressor gene and gene product
12. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression
13. p53 And erbB-2 protein overexpression are early stage alterations in transitional cell carcinoma of the bladder
14. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer
15. Structural basis for epidermal growth factor receptor function
16. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer
17. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
18. c-erbB-2 Oncoprotein expression in primary and advanced breast cancer
19. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma
20. New prognostic factors in patients with esophageal squamous carcinoma
21. Expression of the ERBB2 protein in benign and malignant salivary gland tumors
22. Heterogeneity of erbB-2 gene amplification in bladder cancer
23. Growth fraction in breast carcinoma determined by Ki-67 immunostaining: Correlation with pathological and clinical variables
24. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma
25. c-myc, c-erbB-2, And Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma
26. Breast cancer cell linetics: Immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness
27. Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia
28. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis
29. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas
30. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
31. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques A comparison study between ABC and unlabeled antibody (PAP) procedures
32. Grading of human urothelial carcinoma based on nuclear atypia and mitotic frequency. II. Prognostic importance
33. BrdUrd incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder
34. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining
35. Prognostic factors in bladder carcinoma: Histologic parameters and expression of a cell cycle related nuclear antigen (Ki-67)
36. Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67
37. Cell proliferation of transitional cell bladder cancer determined by PCNA/cyclin immunostaining. A histopathological description
38. Prediction of lymph node metastasis with deoxyribonucleic acid flow cytometry
39. Prognosis of transitional bladder cancer: A multivariate prognostic score for improved prediction
40. Progression and survival in transitional cell bladder cancer: A comparison of established factors, S-phase fraction and DNA ploidy
41. Classic prognostic factors, flow cytometric data, nuclear morphometric variables and mitotic indexes as predictors in transitional cell bladder cancer
42. PCNA and Ki67 expression in breast carcinoma: Correlations with clinical and biological variables
43. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients
44. p53 Expression in breast cancer
45. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas
46. Over-expression of p53 nuclear oncoprotein in colorectal adenomas
47. p53 In colorectal cancer: Clinicopathological correlation and prognostic significance
48. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation
49. p53 Protein expression in central nervous system neoplasms
50. Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas
51. Physical deletion of the p53 gene in bladder cancer: Detection by fluorescence in situ hybridization
52. Participation of p53 protein in the cellular response to DNA damage
53. DNA ploidy and the prognosis of stage pT1 bladder cancer
54. Immunocytochemistry and in situ hybridisation of epidermal growth factor receptor and relation to prognostic factors in breast cancer
55. Epidermal growth factor receptor expression is associated with rapid tumor proliferation in bladder cancer
56. Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer